Category Archives: Other

Reviews that are lab-based (e.g. genes, pharmaceuticals) or on unique groups of people (e.g. fishermen, nurses)

Barriers to HIV remission research in low- and middle-income countries

2017

INTRODUCTION: HIV eradication and remission research has largely taken place in high-income countries. In low- and middle-income countries (LMIC), there may be factors that have a substantial impact on the...

Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades

2016

BACKGROUND: In 2014, the Joint United Nations Programme on HIV and AIDS (UNAIDS) and partners set the ’90-90-90 targets’; aiming to diagnose 90% of all HIV positive people, provide antiretroviral...

The emergence and evolution of the research fronts in HIV/AIDS research

2017

In this paper, we have identified and analyzed the emergence, structure and dynamics of the paradigmatic research fronts that established the fundamentals of the biomedical knowledge on HIV/AIDS. A search...

Atypical presentations of cutaneous leishmaniasis: A systematic review

2017

Cutaneous Leishmaniasis (CL) is endemic in 88 countries, showing relevant prevalences. The aim of this study was to perform a systematic review on atypical lesions of CL around the world,...

HIV and the criminalisation of drug use among people who inject drugs: A systematic review

2017

BACKGROUND: Mounting evidence suggests that laws and policies prohibiting illegal drug use could have a central role in shaping health outcomes among people who inject drugs (PWID). To date, no...

Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review

2017

BACKGROUND: In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment goals for human immunodeficiency virus (HIV). The 90-90-90 target specifies that by 2020, 90% of individuals living...

Performance of point-of-care CD4 testing technologies in resource-constrained settings: A systematic review and meta-analysis

2016

BACKGROUND: Point-of-care (POC) CD4 testing increases patient accessibility to assessment of antiretroviral therapy eligibility. This review evaluates field performance in low and middle-income countries (LMICs) of currently available POC CD4...

Critical review: What dose of rifabutin is recommended with antiretroviral therapy?

2016

Since the advent of combination antiretroviral therapy to successfully treat HIV infection, drug-drug interactions (DDIs) have become a significant problem as many antiretrovirals (ARVs) are metabolized in the liver. Antituberculous...

Host molecular factors and viral genotypes in the mother-to-child HIV-1 transmission in Sub-Saharan Africa

2017

Maternal viral load and immune status, timing and route of delivery, viral subtype, and host genetics are known to influence the transmission, acquisition and disease progression of human immunodeficiency virus-1...

Harm reduction in name, but not substance: A comparative analysis of current Canadian provincial and territorial policy frameworks

2017

BACKGROUND: In Canada, funding, administration, and delivery of health services-including those targeting people who use drugs-are primarily the responsibility of the provinces and territories. Access to harm reduction services varies...

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: Assessing the evidence

2017

Antiretroviral (ARV) therapy, comprising a backbone of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus another ARV, is the recognized standard of care (SOC), which has helped extend life expectancy in...

Geographic distribution and temporal trends of HIV-1 subtypes through heterosexual transmission in China: A systematic review and meta-analysis

2017

Background: Heterosexual transmission (HST) has become the current predominant transmission pathways of the HIV-1 epidemic in China. The aim of this study was to explore the geographic and dynamic change...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!